Juncell Refiles HKEX Main Board Listing; Core Asset GC101 Is World’s First TIL Therapy Without Intensive Lymphodepletion Chemotherapy
NewTimeSpace News: Shanghai Juncell Therapeutics Co., Ltd. resubmitted its Main Board listing application to the Hong Kong Stock Exchange on June 16, with CITIC Securities acting as the sole sponsor. Founded in 2019, it is a biotechnology company focused on solid tumor cell therapies. Its core product GC101 is the world’s first tumor-infiltrating lymphocyte (TIL) therapy that requires neither intensive lymphodepletion chemotherapy nor IL-2 administration. The product is undergoing a registrational Phase II trial for melanoma patients with failed prior PD-1 antibody treatment, and the company expects to file a Biologics License Application (BLA) in 2026.
NewTimeSpace News: According to HKEX disclosures, Shanghai Juncell Therapeutics Co., Ltd. refiled its listing application with HKEX Main Board on 16 June 2026, with CITIC Securities serving as the sole sponsor.
Established in 2019, Juncell Therapeutics is a biotechnology enterprise dedicated to the research, development and commercialization of cell therapies targeting solid tumors. Per Frost & Sullivan data, GC101, the Company’s core candidate, is the world’s first tumor-infiltrating lymphocyte (TIL) therapy free from intensive lymphodepletion chemotherapy and IL-2 infusion, indicated for solid tumors including advanced melanoma and advanced non-small cell lung cancer. GC101 is currently advancing a registrational Phase II clinical trial enrolling melanoma patients who have not responded to PD-1 antibody therapy. The Company plans to submit its BLA in 2026, while the candidate is also being evaluated for other indications and combination treatment regimens.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Hong Kong Credit Corporation (01273.HK): Profit Attributable to Shareholders Expected to Rise 40%–60% Year-on-Year
- MINIEYE Innovation (02431.HK): Signs Procurement Deal for 1,000 Autonomous Logistics Vehicles and Long-Term Cooperation Agreement
- Baixin International (00574.HK): Ma Qinghai Resigns as Executive Director and Chief Executive Officer
- Regent Pacific Group (00575.HK): Senstend™ Approved for Marketing by National Medical Products Administration
- CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted
